Department of Breast Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China.
Department of PET/CT Center, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Molecules. 2021 Oct 29;26(21):6532. doi: 10.3390/molecules26216532.
Breast cancer (BC) is the most common malignant tumor in women worldwide, which seriously threatens women's physical and mental health. In recent years, photodynamic therapy (PDT) has shown significant advantages in cancer treatment. PDT involves activating photosensitizers with appropriate wavelengths of light, producing transient levels of reactive oxygen species (ROS). Compared with free photosensitizers, the use of nanoparticles in PDT shows great advantages in terms of solubility, early degradation, and biodistribution, as well as more effective intercellular penetration and targeted cancer cell uptake. Under the current circumstances, researchers have made promising efforts to develop nanocarrier photosensitizers. Reasonably designed photosensitizer (PS) nanoparticles can be achieved through non-covalent (self-aggregation, interfacial deposition, interfacial polymerization or core-shell embedding and physical adsorption) or covalent (chemical immobilization or coupling) processes and accumulate in certain tumors through passive and/or active targeting. These PS loading methods provide chemical and physical stability to the PS payload. Among nanoparticles, metal nanoparticles have the advantages of high stability, adjustable size, optical properties, and easy surface functionalization, making them more biocompatible in biological applications. In this review, we summarize the current development and application status of photodynamic therapy for breast cancer, especially the latest developments in the application of metal nanocarriers in breast cancer PDT, and highlight some of the recent synergistic therapies, hopefully providing an accessible overview of the current knowledge that may act as a basis for new ideas or systematic evaluations of already promising results.
乳腺癌(BC)是全球女性中最常见的恶性肿瘤,严重威胁着女性的身心健康。近年来,光动力疗法(PDT)在癌症治疗中显示出显著优势。PDT 涉及用适当波长的光激活光敏剂,产生短暂的活性氧(ROS)水平。与游离光敏剂相比,纳米颗粒在 PDT 中的应用在溶解度、早期降解和生物分布方面具有更大的优势,并且能够更有效地穿透细胞间层并摄取靶向癌细胞。在当前情况下,研究人员在开发纳米载体光敏剂方面做出了有希望的努力。通过非共价(自组装、界面沉积、界面聚合或核壳嵌入和物理吸附)或共价(化学固定或偶联)过程合理设计的光敏剂(PS)纳米颗粒,可以实现并通过被动和/或主动靶向在某些肿瘤中积累。这些 PS 加载方法为 PS 有效负载提供了化学和物理稳定性。在纳米颗粒中,金属纳米颗粒具有高稳定性、可调尺寸、光学性质和易于表面功能化的优点,使其在生物应用中更具生物相容性。在这篇综述中,我们总结了光动力疗法治疗乳腺癌的现状和应用,特别是金属纳米载体在乳腺癌 PDT 中应用的最新进展,并强调了一些最近的协同治疗方法,希望能为当前的知识提供一个易于理解的概述,这些知识可能成为新思想的基础,或者对已有希望的结果进行系统评估。